This approach emphasized the use of cardioprotective GLP-1 RAs [liraglutide, dulaglutide, semaglutide, and albiglutide (withdrawn from the market for business reasons)] in T2DM patients with or at high risk for atherosclerotic CVD (ASCVD), heart failure (HF), or chronic kidney disease (12). This evidence concerns the gene GCG and type 2 diabetes mellitus.